BusinessRadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)By Nasdaq OMXOct 20, 2016, 6:30 AM UTC
